Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Arthritis Northwest

Neither a doctor nor a teaching hospital

Research payments

$941,002

46 payments

Through program year 2024, Arthritis Northwest is reported as receiving $941,002 in research payments, across 46 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $48,316 4
2023 Research $198,185 15
2022 Research $108,169 13
2021 Research $130,831 4
2020 Research $253,394 4
2019 Research $202,107 6

Breakdown

Who paid Research payments · program years 2019–2024
  1. Horizon Therapeutics plc $748,806 13 payments
  2. E.R. Squibb & Sons, L.L.C. $114,965 4 payments
  3. AbbVie, Inc. $68,520 25 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $7,000 2 payments
  5. Amgen Inc. $1,641 1 payment
  6. Pfizer Inc. $70 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror Randomized Controlled Trial [RCT]) $213,552 2 payments
  2. A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa Pegloticase Mirror Ol $189,977 1 payment
  3. Infusion Duration Study to Assess Tolerability of Pegloticase Administered With A Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate $151,319 4 payments
  4. Detection, Screening, and Referral of Early RA Patients $99,048 2 payments
  5. A Randomized Double-Blind Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa (Pegloticase) (Mirror Randomized Controlled Trial RCT ) $86,527 1 payment
  6. A Phase 4, Open-Label Study of Krystexxa (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $49,424 1 payment
  7. A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) $44,813 17 payments
  8. A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Krystexxa? (Pegloticase) (Mirror [Ol]) $26,998 1 payment
  9. A Phase 4 Open-Label Study of Krystexxa (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $22,225 1 payment
  10. Phase III PsA Primary Study $15,917 2 payments
What the money was spent on Research payments · program years 2019–2024
  1. Other $7,000 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record